These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30782263)

  • 1. Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients.
    Yoshida T; Yoshida S; Okada H; Suzuki A; Niwa T; Suzuki K; Ohmori T; Kobayashi R; Baba H; Suzuki K; Murakami N; Itoh Y; Ogura S
    Pharmazie; 2019 Feb; 74(2):120-124. PubMed ID: 30782263
    [No Abstract]   [Full Text] [Related]  

  • 2. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients.
    Yoshida S; Suzuki A; Ohmori T; Niwa T; Okada H; Suzuki K; Kobayashi R; Doi T; Kitaichi K; Matsuura K; Murakami N; Ogura S; Itoh Y
    Pharmazie; 2017 Jan; 72(1):53-57. PubMed ID: 29441898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.
    Barbot A; Venisse N; Rayeh F; Bouquet S; Debaene B; Mimoz O
    Intensive Care Med; 2003 Sep; 29(9):1528-34. PubMed ID: 12856119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.
    Brink AJ; Richards GA; Lautenbach EE; Rapeport N; Schillack V; van Niekerk L; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jun; 45(6):647-51. PubMed ID: 25819167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia.
    Mimoz O; Rolland D; Adoun M; Marchand S; Breilh D; Brumpt I; Debaene B; Couet W
    Intensive Care Med; 2006 May; 32(5):775-9. PubMed ID: 16550370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.
    Choi JS; Kim JM; Kim D; Kim SH; Cho H; Park HD; Lee SY; Kang CI; Kim YJ
    J Korean Med Sci; 2020 Nov; 35(46):e376. PubMed ID: 33258328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
    Rouveix B; Jehl F; Drugeon H; Brumpt I; Caulin E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2394-9. PubMed ID: 15215086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin pharmacokinetics in critically ill paediatric patients.
    Sánchez A; López-Herce J; Cueto E; Carrillo A; Moral R
    J Antimicrob Chemother; 1999 Sep; 44(3):407-9. PubMed ID: 10511412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score-].
    Nakano T; Nakamura Y; Togawa A; Takata T; Ishikura H; Mishima K; Futagami K
    Yakugaku Zasshi; 2014; 134(12):1367-73. PubMed ID: 25452245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations of teicoplanin concentrations in neutropenic patients.
    Gimenez F; Leblond V; Nguyen J; Serrand P; Binet JL; Grosset J; Thuillier A
    J Clin Pharm Ther; 1997 Jun; 22(3):187-90. PubMed ID: 9447473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations.
    Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG
    Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.